Search clinical trials for: Fruquintinib RC48

Total 243 results

The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

Gastric Cancer

China
RemeGen Co., Ltd.

Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Gastric Cancer

China
Peking Union Medical College Hospital

Recruiting

Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Salivary Gland Tumors

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Metastatic Breast Cancer

China
RemeGen Co., Ltd.

Completed

Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Solid Tumors

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | RC48 | Disitamab Vedotin

China
Hutchison Medipharma Limited

Withdrawn

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Lung Cancer

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Solid Tumors

China
Zhen-Yu Ding

Completed

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） (DOFEMCRC)

Colorectal Cancer

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Chinese PLA General Hospital

Recruiting

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Advanced Gastroesophageal Adenocarcinoma

China
Fudan University

Recruiting

Fruquintinib in the Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Shanghai Zhongshan Hospital

Recruiting

Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Colo-rectal Cancer

China
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
Wuhan Union Hospital, China

Not yet recruiting

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Stomach Neoplasms

China
RenJi Hospital

Active, not recruiting

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

China
Peking University

Unknown

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...
Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaborators

Not yet recruiting

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Gastric Cancer

China
Sichuan University

Unknown

Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma (FSTAMBTA)

Biliary Tract Adenocarcinoma

China
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Biliary Tract Cancer
Chinese PLA General Hospital

Unknown

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Metastasis Colorectal Cancer

China
Fudan University

Recruiting

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

Colorectal Cancer

China
Hutchmed

Completed

Fruquintinib Renal Impairment Study

Renal Impairment

United States
Hutchmed

Completed

Fruquintinib Hepatic Impairment Study

Hepatic Impairment

United States
RenJi Hospital

Recruiting

RC48-ADC in HER2-low Advanced Breast Cancer

Advanced Breast Cancer

China
RemeGen Co., Ltd.

Not yet recruiting

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Non-small Cell Lung Cancer

China
Hutchmed

Completed

A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients

Patient Safety

China
AIPING ZHOU

Unknown

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Colorectal Cancer

China
Hutchison Medipharma Limited
Fudan University

Completed

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Tumor

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
Huazhong University of Science and Technology

Recruiting

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Colorectal Cancer

China
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Colorectal Cancer

China
Hutchison Medipharma Limited

Completed

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

Food Effect of Fruquintinib in Health Subjects

China
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib

Healthy

China
Seagen Inc.

Recruiting

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Carcinoma, Squamous Cell of Head and Neck

United States, Australia, Canada
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
Peking Union Medical College

Not yet recruiting

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Salivary Gland Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer

Bladder Cancer

China
West China Hospital

Not yet recruiting

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Completed

A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Sun Yat-sen University

Recruiting

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Metastatic Colorectal Cancer

China
Takeda

Available

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer
Peking University People's Hospital

Completed

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Soft Tissue Sarcoma | Bone Sarcoma | Refractory Tumor

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
West China Hospital
RemeGen Co., Ltd.

Not yet recruiting

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

China

3

Subscribe